24518095 Visualization
Back to Main Page
A
44
Age
-
year
Age
-
old
Age
Chinese
Personal_background
man
Sex
with a
7
History
pack
History
-
year
History
smoking
Activity
history
History
was
referred
Clinical_event
to
Shanghai
Nonbiological_location
Pulmonary
Nonbiological_location
Hospital
Nonbiological_location
in
February
Date
2013
Date
for a
left
Biological_structure
upper
Biological_structure
lobe
Biological_structure
lung
Biological_structure
mass
Sign_symptom
with
multiple
Detailed_description
bilateral
Detailed_description
intrapulmonary
Biological_structure
metastases
Sign_symptom
,
left
Detailed_description
pleural
Disease_disorder
effusion
Disease_disorder
, and
2R/4R/10L/11L
Lab_value
lymphadenopathy
Disease_disorder
.
Pleural
Biological_structure
fluid
Biological_structure
cytology
Diagnostic_procedure
revealed
adenocarcinoma
Disease_disorder
and
Scorpion
Diagnostic_procedure
Amplification
Diagnostic_procedure
Refractory
Diagnostic_procedure
Mutation
Diagnostic_procedure
system
Diagnostic_procedure
(
AmoyDx
Detailed_description
Co.,
Detailed_description
Xiamen,
Detailed_description
China
Detailed_description
).showed no detectable
epidermal
Sign_symptom
growth
Sign_symptom
factor
Sign_symptom
receptor
Sign_symptom
mutation
Sign_symptom
.He commenced
chemotherapy
Medication
with
gemcitabine
Medication
and
cisplatin
Medication
.However, after a single cycle, his
symptoms
Sign_symptom
worsened and imaging confirmed
progressive
Detailed_description
disease
Disease_disorder
.A
second
Clinical_event
opinion
Clinical_event
was
Clinical_event
requested
Clinical_event
from the
University
Nonbiological_location
of
Nonbiological_location
Colorado
Nonbiological_location
and a
computed
Detailed_description
tomography
Detailed_description
–
guided
Detailed_description
biopsy
Diagnostic_procedure
of the
left
Biological_structure
upper
Biological_structure
lobe
Biological_structure
lesion
Sign_symptom
was performed to permit additional molecular testing.In the interim, the patient commenced
pemetrexed
Medication
and
nedaplatin
Medication
.Unfortunately, after two cycles his
shortness
Sign_symptom
of
Sign_symptom
breath
Sign_symptom
worsened, with evidence of
further
Sign_symptom
progression
Sign_symptom
on his
scans
Diagnostic_procedure
(Fig.1A).Molecular testing on his repeat
biopsy
Diagnostic_procedure
specimen revealed no
mutations
Sign_symptom
by
SNaPshot
Detailed_description
multiplex
Detailed_description
PCR
Diagnostic_procedure
testing
Diagnostic_procedure
(Life Technologies, Carlsbad, CA).However, although technically negative, the
ALK
Detailed_description
break
Detailed_description
-
apart
Detailed_description
FISH
Diagnostic_procedure
test
Diagnostic_procedure
showed an
atypical
Lab_value
negative
Lab_value
pattern
Lab_value
.Specifically,
68%
Lab_value
of
Lab_value
cells
Lab_value
demonstrated
Lab_value
single
Lab_value
copies
Lab_value
of
Lab_value
the
Lab_value
5′
Lab_value
ALK
Lab_value
signal
Lab_value
and
numerous
Lab_value
cells
Lab_value
with
Lab_value
doublets
Lab_value
of
Lab_value
the
Lab_value
5′
Lab_value
ALK
Lab_value
signal
Lab_value
combined
Lab_value
with
Lab_value
one
Lab_value
3′
Lab_value
ALK
Lab_value
signal
Lab_value
(Fig.2A).Subsequently, confirmatory
diagnostic
Diagnostic_procedure
assays
Diagnostic_procedure
demonstrated
ALK
Lab_value
protein
Lab_value
expression
Lab_value
by
IHC
Diagnostic_procedure
using the
D5F3
Detailed_description
antibody
Detailed_description
(
Cell
Detailed_description
Signaling
Detailed_description
Technology
Detailed_description
Inc.,
Detailed_description
Danvers,
Detailed_description
MA
Detailed_description
; H score = 150; Fig.2B) and the
presence
Lab_value
of
Lab_value
an
Lab_value
echinoderm
Lab_value
microtubule
Lab_value
-
associated
Lab_value
protein
Lab_value
-
like
Lab_value
4
Lab_value
(EML4)-ALK
transcript
Lab_value
(E13; A20) by
RT
Diagnostic_procedure
-
PCR
Diagnostic_procedure
(Fig.2C).The patient then received
crizotinib
Medication
(
250
Dosage
mg
Dosage
twice
Dosage
daily
Dosage
) as third-line therapy in
May
Date
2013
Date
with an impressive
symptomatic
Sign_symptom
improvement
Sign_symptom
and CT response
after
Date
1
Date
month
Date
of therapy (Fig.1B).He remains on treatment with
crizotinib
Medication
with no evidence of
progression
Sign_symptom
as of
September
Date
2013
Date
.